Xeris Biopharma Holdings, Inc. (XERS) Price to Earnings Ratio

Corporate emblem and logo of Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma simplifies the lives of patients with chronic pathologies through the implementation of anhydrous injections. In the long term, the company is optimizing distribution by removing strict temperature requirements from its logistics. Stable production line utilization guarantees the absence of disruptions. The dynamics of the company's P/E ratio visualize this balance, with the metric currently at -468.70, helping to determine the fundamental stability of the asset.

Xeris Pharma (XERS) Price to Earnings Ratio: for the period 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Xeris Biopharma Holdings (XERS)

General company analysis:Xeris Biopharma Holdings, Inc. - XERS
Original product of xerispharma.com

Investors evaluate Xeris Biopharma (XERS) through the lens of cash flow stability driven by patient loyalty to convenient injectable technologies. This ratio compares the current market value of the business to its net income, allowing a price-to-earnings valuation to determine whether the asset is overvalued or undervalued. Analyzing this trend helps balance the risks of market overheating and ensures capital protection against sharp drawdowns.